The present invention relates to nanofibrillar polysaccharide hydrogels for use in the prevention and control of scarring and contraction in connection with wound healing or tissue repair.

Provided herein are chitosan-containing formulations, methods of making such formulations, and methods of using such formulations. Chitosan contemplated for use herein is preferably of high quality and its source is preferably of crustacean origin. The formulations contemplated herein are aqueous, either liquid- or viscous-like, varying in concentration and type of chitosan and acid used, and may include other components. Their uses are diverse, for oral/dental administration or topical/surface application to subjects (e.g. humans or animals) in need thereof or even food commodities, aiming to maintain a good condition where it is applied or contributing to health enhancement, healing, disease prevention or treatment. The present invention also relates to concentrated solutions that may be used for the formulation of other products.

Molecular iodine-infused catheters disclosed herein have biocidal effects and may be used to treat or prevent urinary tract infection (UTI). Other molecular iodine-infused polymers, articles, and products, and their preparation and uses are also disclosed.

The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.

An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds.

Disclosed in the present invention are a preparation method for and a use method of a collagen microfiber hemostatic material. Collagen microfibers are obtained by performing high-speed shearing on a solid collagen material, after the collagen microfibers are dispersed in an aqueous phase, a procoagulant active ingredient modifies the surfaces of the collagen microfibers by means of linking molecules; and a collagen microfiber hemostatic material is obtained by performing high-speed shearing again after freeze drying. The collagen microfiber material can be prepared simply and efficiently by means of high-speed shearing; the biological activity of the collagen material is maintained as much as possible; and the microfibers have a length range of 10-1000 μm and high dispersibility, thus facilitating spray processing. The procoagulant active ingredient can be efficiently and quantitatively loaded on the surfaces of the collagen microfibers by means of the linking molecules to enhance the hemostatic effect of the collagen microfibers. The collagen microfiber hemostatic material prepared in the present invention can be used for hemostasis of a bleeding wound by means of spraying application, thereby achieving the effect of non-contact fixed-point hemostasis.

Systems, devices, compositions, and methods for treating bleeding, for containing blood that has been lost by a subject due to bleeding, and for treating surfaces contaminated with blood or expected to be contaminated with blood are disclosed. The systems, devices, compositions, and methods utilize platelets, platelet-derived materials, or both. The invention includes sprayers, nebulizers, and equivalents, to deliver platelets and/or platelet-derived materials to desired surfaces. Exemplary embodiments include the use of a pressurized sprayer configured to deliver a topical administration of a lyophilized platelet and/or platelet-derived material to a surface.

An antiseptic solution including, a cationic antiseptic agent, a film forming polymer, an anionic tinting agent, and a solvent, wherein the cationic antiseptic agent, the film forming polymer and the anionic tinting agent each remain solubilized within the solution for greater than about 1 hour at 25° C. and 60% relative humidity. The antiseptic agent is preferably octenidine dihydrochloride or chlorhexadine gluconate. The film forming polymer is preferably an acrylate polymer. The solvent is preferably ethanol, isopropanol, and n-propanol. When a drape is adhered to a dried surgical film via the antiseptic solution, the force required to peel the drape from the surgical film is at least about 105 g/25 mm.

A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.

The present invention pertains to use of sodium diacetate (NaHAc.sub.2) as an antimicrobial agent against bacteria growing in biofilms. The aspects of the invention include a wound care product comprising sodium diacetate, a kit comprising a wound care product, and a method of treating an infected wound.